Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 7/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KYAT1 | Q16773 | 6/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901608 | 1.00 | GAA (0.63) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL5253476 | 1.00 | GAA (0.63) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL11767611 | 0.87 | KYAT1 (0.60) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL16730420 | 0.87 | KYAT1 (0.60) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL11767616 | 0.87 | KYAT1 (0.60) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL16361794 | 0.86 | MEN1 (0.65) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL3560755 | 0.86 | MEN1 (0.65) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL3560757 | 0.86 | MEN1 (0.65) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL2487154 | 0.85 | KYAT1 (0.52) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL1998080 | 0.85 | KYAT1 (0.52) | GAALMNAALDH1A1NPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329651-B2 | Cannabimimetic ligands | UNIVERSITY OF CONNECTICUT (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1805179-A2 | PREPARATION OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES | Brystol-Myers Squibb Company (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006135425-A2 | PREPARATION OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060069085-A1 | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069085-A1 | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | F2, TFPI, TFPI2 | GAA 2145/4885LMNA 578/4885ALDH1A1 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.